Apollomics Inc
APLM
Company Profile
Business description
Apollomics Inc is an clinical-stage biopharmaceutical company focused on the discovery and development of oncology therapies with the potential to be combined with other treatment options to harness the immune system and target specific molecular pathways to inhibit cancer. The company programs include vebreltinib (APL-101), a potent, selective c-Met inhibitor for the treatment of non-small cell lung cancer and other tumors with c-Met alterations, and uproleselan (APL-106), a specific E-Selectin antagonist that has the potential to be used adjunctively with standard chemotherapy to treat acute myeloid leukemia.
Contact
989 East Hillsdale Boulevard
Suite 220
FosterCA94404
USAT: +1 650 209-4055
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
13
Stocks News & Analysis
stocks
Has the most hated company on the ASX 200 bounced back?
Encouraging results indicate a potential turnaround story.
stocks
Amazon earnings: Good results, with AWS still a winner; fear on profitability guidance is overblown
We think Amazon stock looks attractive.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,922.00 | 77.00 | -0.86% |
| CAC 40 | 7,630.10 | 83.94 | 1.11% |
| DAX 40 | 23,757.28 | 331.31 | 1.41% |
| Dow JONES (US) | 44,070.51 | 60.47 | -0.14% |
| FTSE 100 | 9,127.08 | 5.73 | -0.06% |
| HKSE | 24,733.45 | 39.88 | -0.16% |
| NASDAQ | 20,971.09 | 320.95 | 1.55% |
| Nikkei 225 | 40,290.70 | 779.12 | -1.90% |
| NZX 50 Index | 12,684.04 | 139.70 | -1.09% |
| S&P 500 | 6,311.97 | 73.96 | 1.19% |
| S&P/ASX 200 | 8,663.70 | 79.10 | -0.90% |
| SSE Composite Index | 3,583.31 | 23.36 | 0.66% |